This abstract discusses the efficacy and safety outcomes from the Phase 1b/2 STOMP trial evaluating selinexor in combination with pomalidomide and dexamethasone (SPd) for relapsed/refractory multiple myeloma (RRMM). Results show promising overall response rates (ORR), particularly in the SPd60 cohort, along with manageable adverse events such as neutropenia and fatigue. The study underscores the potential of selinexor as a therapeutic option in heavily pretreated MM patients.

Key Points:

• ORR of 39.5%, VGPR or better in 19.8% of patients.
• Common TEAEs included neutropenia, fatigue, nausea, anemia, and thrombocytopenia.
• Median age 65, median 3 prior lines of therapy.
• Phase 1b/2 STOMP trial evaluating selinexor in SPd regimens.
• SPd showed preliminary efficacy with manageable safety profile in RRMM.
• Supports further investigation of low-dose weekly selinexor in ongoing trials.

Authors:
Muhamed Baljevic, MD; Nizar J. Bahlis, MD; Rami Kotb, MD; Gary J. Schiller, MD; Brea Lipe, MD; Sumit Madan, MD; Heather J. Sutherland, MD, PhD, FRCPC; Suzanne Lentzsch, MD, PhD; Natalie Callander, MD; Noa Biran, MD